Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifecta Research Study
NCT06810765Phase 2Withdrawn
- Sponsor
- Johns Hopkins University
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ibogaine and 5-MeO-DMT in post-traumatic stress disorder (PTSD), traumatic brain injury (TBI) and cognitive dysfunction (2 arms), sponsored by Johns Hopkins University. Primary endpoints: PTSD Checklist for DSM-5 at 12 months, Medical Outcomes Study Cognitive Functioning Scale at 12 months and 3 more. Planned start Sep 2025; status: withdrawn.
02
Drugs
ibogaine5-MeO-DMT
03
Conditions
post-traumatic stress disorder (PTSD)traumatic brain injury (TBI)cognitive dysfunction
Beyond the preview
Go deeper on NCT06810765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06810765.